Evidence map›Paper›PMID 35433464›Full record

ArticleFrontiers in oncology2022

miR-139-5p Was Identified as Biomarker of Different Molecular Subtypes of Breast Carcinoma.

Haohang Sun, Ji Dai, Mengze Chen, Qi Chen, Qiong Xie, Weijun Zhang, Guoqing Li, Meidi Yan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Potassium Channels, Glucose Metabolism and Glycosylation in Cancer Cells.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haohang SunGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Ji DaiDepartment of General Surgery, Zhenhai District People's Hospital, Ningbo, China.
Mengze ChenGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Qi ChenGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Qiong XieGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Weijun ZhangGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Guoqing LiGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.
Meidi YanGeneral Surgery I (Thyroid, Breast, Vascular, Hernia Surgery), General Hospital of Zhenhai District People's Hospital Medical Group, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Located on chromosome 11q13.4, miR-139-5p has been confirmed by several studies as a possible attractive biomarker for cancer, including breast cancer, but its mechanism of correlation in different molecular subtypes of breast cancer has not been reported. In this study, comprehensive bioinformatics analysis was used to evaluate the expression of miR-139-5p in different molecular subtypes of breast cancer (luminal A, luminal B, HER2-enriched, and basal-like). The target genes of miR-139-5p were predicted by using an online database TargetScan and miRDB, and three key genes, FBN2, MEX3A, and TPD52, were screened in combination with differentially expressed genes in different molecular subtypes of breast cancer. The expression of the three genes was verified separately, and the genes were analyzed for pathway and functional enrichment. Bone marrow mesenchymal stem cells (BMSC) are another kind of highly plastic cell population existing in bone marrow besides hematopoietic stem cells. BMSC can affect the proliferation and migration of cancer cells, promote the metastasis and development of cancer, and regulate the tumor microenvironment by secreting exosome mirnas, thus affecting the malignant biological behavior of tumor cells. Finally, human bone marrow mesenchymal stem cells exosomes were obtained by ultracentrifugation, and the morphology of exosomes was observed by transmission electron microscopy. The expression of miR-139-5p in normal breast cells MCF-10A, human breast cancer cell line MDA-MB-231 cells, and BMSCs-derived exosomes were compared; the exosomes and MDA-MB-231 cells were co-cultured to observe their effects on the proliferation of the MDA-MB-231 cells. Human bone marrow mesenchymal stem cell-derived exosomes inhibited the growth of breast cancer cells and promoted the expression of FBN2, MEX3A, and TPD52 by transporting miR-139-5p.

Indexed as

breast carcinomaexosomesmesenchymal stem cellsmiR-139-5pmolecular isoforms

Identifiers

PMID35433464
PMCPMC9009410
OpenAlexW4220921652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.